July 21, 2020 Research Bulletin
Volume 1, Issue 5
| News | Events |
|
|
Featured Funding Opportunities
Program: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 – Clinical Trial Required)
LOI Due: September 2
Collaborative Research Opportunities
Stand Up To Cancer (SU2C)
About SU2C: Stand Up To Cancer breaks down the traditional barriers to collaboration by allowing scientists ad researchers across institutions and disciplines to come together and work toward a shared goal: beating cancer.
What's New at Stand Up To Cancer Program: Health Equity Breakthrough Team Research Grant Program
LOI Due: September 1
Interested in collaborative research? Do you have a collaborative research funding opportunity you would like to announce or are you searching for a collaborator on a specific proposal?
Collaborations between research groups are growing, and the collaborating groups can be across the hall, University of Colorado campuses, the country, or the globe. Scholars or groups in different fields work together on interdisciplinary projects.
The OVCR wants to offer this space on a bi-weekly basis for promotion of collaborative research funding opportunities (internal and external funding) and solicitations for prospective interdisciplinary collaborators for proposed funding applications.
Send inquires to ResearchAdminComm@CUAnschutz.edu
NIH Funding Announcements
NIH funding opportunities and notices are presented weekly. Rather than sending a separate email those updates will now be provided in this section.
Just Released Funding Opportunities
The High-Risk High-Reward Research Program and other Common Fund programs are managed by the Office of Strategic Coordination, Division of Program Coordination, Planning, and Strategic Initiatives in the NIH Office of the Director, in partnership with
the component NIH Institutes, Centers, and Offices. The NIH Common Fund encourages collaboration and supports a series of exceptionally high impact, trans-NIH programs.
The National Institutes of Health (NIH) –“The Nation's Medical Research Agency” – includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for
conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases.
For more information about NIH and its programs, visit the NIH website.
FY2021 NIH Director’s Transformative Research Award (R01 - Clinical Trial Optional):
RFA RM-20-013
Supports individuals or teams proposing that are inherently risky and untested but have the potential to create or overturn fundamental paradigms. An anonymized review process will be used.
- Open to all career stages
- Application deadline: September 30
FY2021 NIH Director’s Emergency Transformative Research Award (R01 - Clinical Trial Optional): COVID-19 Proposals
RFA RM-20-020
Supports individuals or teams proposing COVID-19-related projects that are inherently risky and untested but have the potential to create or overturn fundamental paradigms. An anonymized review process will be used.
- Open to all career stages
- Application deadline: September 30
Special Announcements
CU Anschutz and CU Boulder Research (AB Nexus) Collaboration Update
On Friday, July 31 at 8am there will be an information session regarding the launch of the CU Anschutz and CU Boulder Collaborative Research Initiative.
Vice Chancellor of Research, CU Anschutz, Dr. Thomas Flaig and Vice Chancellor of Research and Innovation, CU Boulder, Dr. Terri Fiez will lead the discussion, which will be hosted on Zoom.
CU Cancer Center Research May Explain Why Some COVID-19 Patients Take Months to Recover
This highlights research published in medRxiv.
This bulletin is distributed on the 1st & 3rd Tuesday of the month for the CU Anschutz Research Community.
Past Research Bulletins can be found here.
Please click here if you wish to be added to this distribution.